ReceptoPharm  
Home   Drug Development   Newsroom   About ReceptoPharm   Contact
» Overview
» Research Platform
» R&D Pipeline
» Published Research
» Licensing
 
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
 

R&D Pipeline

ReceptoPharm's research and development pipeline consists of several novel therapies in various stages of development to prevent and/or treat Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN), Herpes, Rheumatoid Arthritis (RA) and Pain.

 
Planning
 
 
In Progress
 
 
Completed
 

Abbreviations
Preclinical (PC), Phase 1 (P-I), Phase 2 (P-II), Phase 3 (P-III)

RPI-78M

 
Indication
PC
P-I
P-II
P-III
       
  Herpes Simplex Infections 1 & 2      
         
     

RPI-MN

 
Indication
PC
P-I
P-II
P-III
         
 
Human Immunodeficiency Virus
   
 

Amyotrophic Lateral Sclerosis

       
  Herpes Simplex Keratitis        

RPI-78

 
Indication
PC
P-I
P-II
P-III
         
     

Cobroxin

 
Indication
Regulatory Status
 
Chronic Pain (OTC)
Marketing

 
Pet Pain-Away
Pet Pain-Away is the first over-the-counter pain reliever proven to safely relieve pain in companion anmimals. Formulated to safely and naturally relieve your pet's joint pain, stiffness, swelling, and inflammation, Pet Pain Away helps support mobility, flexibility, and a healthy lifestyle overall .For more information, visit https://www.petpainaway.com.

Nyloxin

 
Indication
Regulatory Status
 
Chronic Pain (OTC)
Marketing

 
Nyloxin // Chronic Pain Relief
Nyloxin is an over-the-counter (OTC) pain reliever for the treatmentment of moderate to severe chronic pain. It is available as both an oral spray and as a topical gel. Nyloxin is specifically formulated to treat back pain, neck pain, headaches, joint pain, migraines, arthritis pain, pain from repetitive stress and neuralgia. For more information, visit http://www.Nyloxin.com.

 

 
E-Alerts
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name:
Email:
NPC